The muscle regeneration marker FOXP3 is associated with muscle injury in Duchenne muscular dystrophy
Copyright © 2024 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved..
BACKGROUND: In Duchenne muscular dystrophy (DMD), the immune system cells (ISC) synthesize molecules to regulate inflammation, a process needed to regenerate muscle. The relationship between those molecules and the muscle injury is unknown. Monocytes belonging to ISC are regulated by omega-3 fatty acids (ω-3 LCPUFAs) in DMD, but whether those fatty acids influence other ISC like T-cells is unknown.
OBJECTIVE: We analyzed the expression of the muscle regeneration markers (FOXP3 and AREG) in circulating leukocytes of DMD patients with different lower limb muscle functions and whether ω-3 LCPUFAs regulate the expression of those markers, and the populations of circulating T-cells, their intracellular cytokines, and disease progression (CD69 and CD49d) markers.
METHODS: This placebo-controlled, double-blind, randomized study was conducted in DMD boys supplemented with ω-3 LCPUFAs (n = 18) or placebo (sunflower oil, n = 13) for six months. FOXP3 and AREG mRNA expression in leukocytes, immunophenotyping of T-cell populations, CD49d and CD69 markers, and intracellular cytokines in blood samples were analyzed at baseline and months 1, 2, 3, and 6 of supplementation.
RESULTS: Patients with assisted ambulation expressed higher (P = 0.015) FOXP3 mRNA levels than ambulatory patients. The FOXP3 mRNA expression correlated (Rho = -0.526, P = 0.03) with the Vignos scale score at month six of supplementation with ω-3 LCPUFAs. CD49d + CD8 + T-cells population was lower (P = 0.037) in the ω -3 LCPUFAs group than placebo at month six of supplementation.
CONCLUSION: FOXP3 is highly expressed in circulating leukocytes of DMD patients with the worst muscle function. Omega-3 LCPUFAs might modulate the synthesis of the adhesion marker CD49d + CD8 + T-cells, but their plausible impact on FOXP3 needs more research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Brain & development - 46(2024), 5 vom: 28. März, Seite 199-206 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yannin Hernández-de la Cruz, Sthephanie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.braindev.2024.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368782875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368782875 | ||
| 003 | DE-627 | ||
| 005 | 20240326235516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.braindev.2024.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368782875 | ||
| 035 | |a (NLM)38388302 | ||
| 035 | |a (PII)S0387-7604(24)00027-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yannin Hernández-de la Cruz, Sthephanie |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The muscle regeneration marker FOXP3 is associated with muscle injury in Duchenne muscular dystrophy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: In Duchenne muscular dystrophy (DMD), the immune system cells (ISC) synthesize molecules to regulate inflammation, a process needed to regenerate muscle. The relationship between those molecules and the muscle injury is unknown. Monocytes belonging to ISC are regulated by omega-3 fatty acids (ω-3 LCPUFAs) in DMD, but whether those fatty acids influence other ISC like T-cells is unknown | ||
| 520 | |a OBJECTIVE: We analyzed the expression of the muscle regeneration markers (FOXP3 and AREG) in circulating leukocytes of DMD patients with different lower limb muscle functions and whether ω-3 LCPUFAs regulate the expression of those markers, and the populations of circulating T-cells, their intracellular cytokines, and disease progression (CD69 and CD49d) markers | ||
| 520 | |a METHODS: This placebo-controlled, double-blind, randomized study was conducted in DMD boys supplemented with ω-3 LCPUFAs (n = 18) or placebo (sunflower oil, n = 13) for six months. FOXP3 and AREG mRNA expression in leukocytes, immunophenotyping of T-cell populations, CD49d and CD69 markers, and intracellular cytokines in blood samples were analyzed at baseline and months 1, 2, 3, and 6 of supplementation | ||
| 520 | |a RESULTS: Patients with assisted ambulation expressed higher (P = 0.015) FOXP3 mRNA levels than ambulatory patients. The FOXP3 mRNA expression correlated (Rho = -0.526, P = 0.03) with the Vignos scale score at month six of supplementation with ω-3 LCPUFAs. CD49d + CD8 + T-cells population was lower (P = 0.037) in the ω -3 LCPUFAs group than placebo at month six of supplementation | ||
| 520 | |a CONCLUSION: FOXP3 is highly expressed in circulating leukocytes of DMD patients with the worst muscle function. Omega-3 LCPUFAs might modulate the synthesis of the adhesion marker CD49d + CD8 + T-cells, but their plausible impact on FOXP3 needs more research | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amphiregulin | |
| 650 | 4 | |a Duchenne muscular dystrophy | |
| 650 | 4 | |a Forkhead box P3 | |
| 650 | 4 | |a Muscle injury | |
| 650 | 4 | |a Omega-3 long-chain polyunsaturated fatty acids | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Forkhead Transcription Factors |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a FOXP3 protein, human |2 NLM | |
| 700 | 1 | |a Ordaz-Robles, Thania |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio Villaldama-Soriano, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Emmanuel Luna-Guzmán, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida-Becerril, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Villa-Morales, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Cárdenas-Conejo, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Dolores Ruíz-Cruz, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado-Hernandez, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Bernabe-Garcia, Mariela |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa-Cortés, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Cruz, Maricela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain & development |d 1985 |g 46(2024), 5 vom: 28. März, Seite 199-206 |w (DE-627)NLM000465461 |x 1872-7131 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:5 |g day:28 |g month:03 |g pages:199-206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.braindev.2024.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 5 |b 28 |c 03 |h 199-206 | ||